pfizer oral glp 1 does have a drug Danuglipron: An GLP-1R Agonist Competing with Peptide Pfizer axes oral GLP-1 asset,

Drink plenty of water Regular fluid intake prevents dehydration, reducing the risk of constipation

Additional agents are being studied with the aim of improving care in the future, allowing for more targeted and appropriate treatment with even greater potential for the individualization of therapy

Anyone else seeing this tension in practice

A recent explored the effects GLP-1 agonists had on a case series of 47 patients with mast cell activation syndrome (MCAS)

Phase 3 TRIUMPH trial data on long-term discontinuation effects are still emerging as of 2026

143: 43974408 [DOI] [PubMed] [Google Scholar] 86.Wang Q, Brubaker PL